CD4 and Thrombocytopenia: The protection by molnupiravir was associated with lower virus burden in mouse tissues, improvement of T-cell (CD4<sup>+</sup>, CD8<sup>+</sup>) and B-cell (follicular) profiles in the spleen, improvement of severe thrombocytopenia, and reduced pathology in the spleen and liver of BRBV-infected mice.